STEVEN L. HIGHLANDER PARTNER

INTERNET ADDRESS: SHIGHLANDER@FULBRIGHT.COM

DIRECT DIAL: 512/536-3184

May 23, 2001

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP 600 CONGRESS AVENUE, SUITE 2400 AUSTIN, TEXAS 78701

HOUSTON
VASHINGTON, D.C
AUSTIN
SAN ANTONIO
DALLAS
NEW YORK
LOS ANGELES
MINNEAPOLIS
LONDON

HONG KONG

GAU 1632

RECEIVED

JUN 0 1 2001

TECH CENTER 1600/2900 FILE: UTSD:566US

CERTIFICATE OF MAILING 37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 2021, on the date below:

May 23, 2001

Date

Steven L. Highlander

Commissioner for Patents Washington, DC 20231

RE:

SN 09/780,575 "SELECTIONS OF PEPTIDES WITH ANTIBODY-LIKE PROPERTIES" - Thomas J. Kodadek

Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, Form PTO-1449, and references (C1-C41).

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10100183/SLH.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,


Steven L. Highlander Reg. No. 37,642

SLH/mar

Encl: as noted

25033975.1







CERTIFICATE OF MAILING 37 C.F.R. 1.8 TECH CENTER 1600/2900

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents,

Washington, DC 20231, on the date below:

May 23, 2001

Date

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Thomas J. Kodadek

Serial No.: 09/780,575

Filed: February 9, 2001

For: SELECTIONS OF PEPTIDES WITH ANTIBODY-LIKE PROPERTIES

Group Art Unit: 1632

n L. Highlander

Examiner: Unknown

Atty. Dkt. No.: UTSD:566US/SLH

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be

an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10100183/SLH.

Applicant respectfully requests that the listed documents be made of record in the present

Case.

PE CITIS TRADENTE

FULBRIGHT & JAWORSKI L.L.P. 600 Congress Avenue, Suite 2400 Austin, Texas 78701 (512) 474-5201

Date:

May 23, 2001

Respectfully submitted,

Steven L. Highlander Reg. No. 37,642

Attorney for Applicant

· r	OIPE
	mm o
Form PTO-1449 (modified	MAY 13
List of Patents and Publica	tions for Application's

List of Patents and Publications for Application's Applicant
Thomas J. Kodadek

Atty. Docket No.

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant		
Thomas J. Kodadek		ÄNTE
Filing Date:	Group:	
February 9, 2001	1632	1600

Serial No.

U.S. Patent Documents Foreign Patent Documents Other Art
See Page 1 See Page 1 See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Borman, "Combinatorial chemistry", Chem. & Eng. News, 75:43-62, 1997.
	C2	Burger and Still, "Simple strucutral requirements for sequence-selective peptide receptors? Tripeptide binding by a podand ionophore", J. Org. Chem., 62:4785-4790, 1997.
	C3	Burton, "Phage display", Immunotechnology, 1:87-94, 1995.
	C4	Cairns et al., "A novel bacterial vector system for monitoring protein-protein interactions in the cAMP-dependent protein kinase complex", Gene, 185:5-9, 1997.
	C5	Chen et al., "Fluorescent, sequence-selective peptide detection by synthetic small molecules", <i>Science</i> , 279:851-853, 1998.
	C6	Cheng et al., "Sequence-selective peptide binding with peptido-A,B-trans-steroidal receptor selected from an encoded combinatorial receptor library". J. Amer. Chem. Soc., 118:1813-1814, 1996.
	C7	Dinarello, "Interleukin-β, interleukin-18 and the interleukin-1β converting enzyme", Ann. N. Y. Acad. Sci., 856:1-11, 1998.
	C8	Dong et al., "Molecular forceps from combinatorial libraries prevent the farnesylation of Ras by binding to its carboxyl terminus", <i>Chem. & Biol.</i> , 6:133-141, 1999.
***	C9	Dove et al., "Conversion of the ω subunit of Eschericia coli RNA polymerase into a transcriptional activator or activation target," Gene and Development, 12:745-754, 1998.

25018982.1

	· · · · · · · · · · · · · · · · · · ·
Examiner:	DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

	OIFE
Form PTO-1449 (modified	PMI 2
List of Patents and Publica	tions for Applicant's
INFORMATION DISC	LOSURE STATEMENT

Atty. Docket No.	Serial No.	
UTSD:566US/SLH 09/780,575		젊
Applicant		오
Thomas J. Kodadek		CENTER
Filing Date:	Group:	<u></u>
February 9, 2001	1632	

(Use several sheets if necessary)

U.S. Patent Documents See Page 1

Foreign Patent Documents See Page 1

Other Art See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C10	Fairbrother et al., "Novel peptides selected to bind vascular endothelial growth factor target the receptor-binding site", <i>Biochemistry</i> , 37:17754-17764, 1998.
	C11	Fancy and Kodadek, "Chemistry for the analysis of protein-protein interactions: Rapid and efficient cross-linking triggered by long wavelength light," <i>Proc. Natl. Acad. Sci. USA</i> , 96:6020-6024, 1999.
	C12	Fields and Song, "A novel genetic system to detect protein-protein interactions," <i>Nature</i> , 340:245-246, 1989.
:	C13	Fodor, "Light-directed, spatially addressable parallel chemical synthesis," <i>Science</i> , 251:767-773, 1991.
:	C14	Griffiths and Duncan, "Strategies for selection of antibodies by phage display," Curr. Opin. Biotechnol., 9:102-108, 1998.
	C15	Hajduk et al., "Discovery of potent nonpeptide inhibitors of stromelysin using SAR by NMR," J. Amer. Chem. Soc., 119:5818-5827, 1997.
<u>.</u>	C16	Han and Kodadek, "Peptides selected to bind the Gal80 repressor are potent transcriptoinal activation domains in yeast," J. Biol. Chem., 275:14979-14984, 2000.
	C17	Harland and Weintraub, "Translation of mRNA injected into Xenopus oocytes is specifically inhibited by antisense RNA," J. Cell Biol., 101:1094-1099, 1985.
	C18	He et al., "Transformation of wheat (Triticum aestivum L.) through electroporation of protoplasts," Plant Cell Reports, 14:192-196, 1994.
	C19	Hossain and Schneider, "Sequence-selective evaluation of peptide side-chain interaction. New artificial receptors for selective recognition in water," J. Amer. Chem. Soc., 120:11208-11209, 1998.
-	C20	Hu et al., "Sequence requirements for coiled-coils: Analysis with λ Repressor-GCN4 leucine zipper fusions," Science, 250:1400-1403, 1990.
	C21	Hu, "Repressor fusions as a tool to study protein-protein interactions," Structure, 3:431-433, 1995.
	C22	Jappelli and Brenner, "Interaction between cAMP-dependent protein kinase catalytic subunit and peptide inhibitors analyzed with λ Repressor fusions," J. Mol. Biol., 259:575-578, 1996.

25018982.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified MAY 2 9 2001 List of Patents and Publications for Applications of Papents 19 2001 Practical Practical

Atty. Docket No. Serial No. UTSD:566US/SLH 09/780,575

Applicant

Thomas J. Kodadek

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date: February 9, 2001 Group: 1632

U.S. Patent Documents
See Page 1

Foreign Patent Documents
See Page 1

Other Art See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C23	Kim et al., "Photo-induced protein cross-linking mediated by palladium porphyrins," J. Amer. Chem. Soc., 121:11896-11897, 1999.
	C24	Kodadek, "Protein microarrays: prospects and problems," Chem. & Biol., 64:1-11, 2001.
	C25	Maly et al., "Combinatorial target-guided ligand assembly: identification of potent subtype-selective c-Src inhibitors," <i>Proc. Natl. Acad. Sci. USA</i> , 97:2419-2424, 2000.
	C26	Mikolajczyk et al., "High yield, site-specific coupling of N-terminally modified β-lactamase to a proteolytically-derived single-sulfhydryl murine fab," <i>Biooconj. Chem.</i> , 5:636-646, 1994.
• • • •	C27	O'Brian-Simpson, "Polymerization of unprotected synthetic peptides: A view towards synthetic peptide vaccines," J. Amer. Chem. Soc., 119:1183-1188, 1997.
	C28	Park and Raines, "Genetic selection for dissociative inhibitors of designated protein-protein interactions," <i>Nature Biotechnol</i> ," 18:847-851, 2000.
	C29	Rader and Barbas, "Phage display of combinatorial antibody libraries," Curr. Opin. Biotechnol., 8:503-508, 1997.
	C30	Rose, "Natural peptides as building blocks for the synthesis of large protein-like molecules with hydrazone and oxime linkages," <i>Bioconj. Chem.</i> , 7:552-556, 1996.
	C31	Sasaki et al., "A new application of a peptide library to identify selective interaction between small peptides in an attempt to develop recognition molecules toward protein surfaces," <i>Tetrahedron Letters</i> , 37:85-88, 1996.
• • •	C32	Schneider et al., "Scaffold-hopping: by topological pharmacophore search: a contribution to virtual screening," <i>Angew Chem Int Ed Engl.</i> , 38:2894-2896, 1999.
	C33	Shao et al., "Sequence-selective receptors of peptides. A simple molecular design for construction of large combinatorial libraries of receptors," J. Org. Chem., 61:6086-6087, 1996.
	C34	Shuker et al., "Discovering high-affinity ligands for proteins: SAR by NMR," Science, 274:531-1534, 1996.
	C35	Still, "Discovery of sequence-selective peptide binding by synthetic receptors using encoded combinatorial libraries," Acc. Chem. Res., 29:155-163, 1996.
	C36	Xie et al., "Biochemical characterization of the TATA-binding Gal4 activation domain complex," <i>JBC</i> , 275:31914-31920, 2000.

25018982.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

		C173
Form PTO-1449 (modified)	MAY 29	FICE
List of Patents and Publicat	ion for App	olicant's

's Ap

Serial No. 09/780,575

Applicant

Thomas J. Kodadek

Atty. Docket No. UTSD:566US/SLH

(Use several sheets if necessary)

INFORMATION DISCLOSURE STATEMENT

Filing Date: February 9, 2001 Group: 1632

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C37	Yang et al., "Protein-peptide interactions analyzed with the yeast two-hybrid system," <i>Nucl. Acids Res.</i> , 23:1152-1156, 1995.
	C38	Zhang et al., "An inhibitor of sequence specific proteolysis that targets the substrate rather than the enzyme," Chem. Biol., 8:391-397, 2001.
	C39	Zhang et al., "Genetic selection of short peptides that support protein oligomerization in vivo. Current Biol.," 9:417-420, 1999.
	C40	Zhang, "Selection and practical applications of peptide-binding peptides," <i>Nature Biotechnol.</i> , 18:71-74, 2000.
	C41	Zhu, "A Cdc6 protein-binding peptide selected using a bacterial two-hybrid-like system is a cell cycle inhibitor," J. Biol. Chem., 275:32098-32105, 2000.

25018982.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.